Elacestrant
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-ELACESTRANT |
|---|---|
| Type | Drug |
| Aliases | OrserduЕлацестрант |
| Status | pending_clinical_signoff |
| Diseases | DIS-BREAST |
| Sources | SRC-ESMO-BREAST-METASTATIC-2024 SRC-NCCN-BREAST-2025 |
Drug Facts
| Class | Oral SERD (selective estrogen receptor degrader) |
|---|---|
| Mechanism | First-in-class oral SERD. EMERALD trial: elacestrant superior to fulvestrant or AI in ESR1-mutant HR+/HER2- metastatic post-CDK4/6i. |
| Typical dosing | 345 mg PO once daily with food. |
| Ukraine registered | False |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-04-27 |
Notes
Indication: ESR1-mutant HR+/HER2- metastatic after at least one prior endocrine therapy. ESR1 mutation testing on ctDNA recommended pre-start.
Used By
Regimens
REG-ELACESTRANT-BREAST- Elacestrant monotherapy (HR+/HER2- ESR1-mutant metastatic post-AI/CDK4/6i)